Comparison of costs associated with transcatheter mitral valve repair: PASCAL vs MitraClip in a real-world setting.

BMC Health Serv Res

Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Published: September 2023

AI Article Synopsis

  • The study aimed to evaluate the costs associated with mitral valve transcatheter edge-to-edge repair (M-TEER) treatments using the MitraClip and PASCAL systems through a clinical process cost analysis.
  • A total of 107 M-TEER patients were prospectively analyzed for in-hospital costs, while a retrospective analysis of 716 procedures looked at complications and costs associated with materials used during the procedures.
  • Results showed that the main cost driver was material expenditure, particularly device costs, with no significant differences in overall costs between the two systems, and complications led to additional costs primarily from extended hospital stays.

Article Abstract

Aims: We aimed to conduct a clinical process cost analysis to evaluate all upcoming costs of mitral valve transcatheter edge-to-edge repair (M-TEER) treatment using the MitraClip and the PASCAL repair system.

Methods: First, we prospectively enrolled 107 M-TEER patients treated with either the PASCAL or MitraClip system and compared all upcoming costs during the M-TEER procedure and the associated in-hospital stay. Second, we retrospectively analysed 716 M-TEER procedures with regard to the occurrence of complications and their associated costs. All materials used in the catheterization laboratory for the procedures were evaluated. The cost analysis considered various expenses, such as general in-hospital costs, device costs, catheter laboratory and material costs.

Results: In the prospective study, 51 patients were treated using the PASCAL system, and 56 were treated using the MitraClip system. The two groups had comparable baseline characteristics and comorbidities. The total in-hospital costs were 25 414 (Interquartile range (IQR) 24 631, 27 697) € in the PASCAL group and 25 633 (IQR 24 752, 28 256) € in the MitraClip group (p = 0.515). The major cost driver was initial material expenditure, mostly triggered by device costs, which were similar to the PASCAL and MitraClip systems. Overall intensive care unit and general ward costs did not differ between the PASCAL and MitraClip groups. In the retrospective analysis, M-TEER-related complications were rare but were associated with higher costs, mainly due to prolonged hospitalisation.

Conclusion: The major cost driver of M-TEER was the material expenditure, which was mostly triggered by high device costs. The costs of treating patients were similar for the PASCAL and MitraClip systems. M-TEER-related complications are associated with higher costs, mainly due to prolonged hospitalisation. This analysis provides valuable insights into reducing expenses by modifying the process of M-TEER.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476289PMC
http://dx.doi.org/10.1186/s12913-023-09966-8DOI Listing

Publication Analysis

Top Keywords

pascal mitraclip
20
costs
12
device costs
12
mitral valve
8
pascal
8
mitraclip
8
cost analysis
8
upcoming costs
8
patients treated
8
treated pascal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!